Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484747 | 0.69 | GRM2 (0.39) | ELANEGRM2CTSGPRTN3LMNA | |
| SCHEMBL4465167 | 0.67 | CCR5 (0.32) | ELANEGRM2CTSGPRTN3LMNA | |
| SCHEMBL4454008 | 0.64 | OPRM1 (0.40) | NPSR1GRM2KMT2AALDH1A1CYP2C19 | |
| SCHEMBL4482455 | 0.63 | ELANE (0.42) | ELANENPSR1CTSGPRTN3LMNA | |
| SCHEMBL4914793 | 0.62 | MDM2 (0.67) | ALDH1A1 | |
| SCHEMBL4322743 | 0.62 | CYP2C9 (0.38) | ELANENPSR1CTSGPRTN3LMNA | |
| SCHEMBL4455569 | 0.62 | OPRM1 (0.42) | GRM2KMT2AALDH1A1CYP2C19MEN1 | |
| SCHEMBL22222447 | 0.61 | EHMT2 (0.42) | ELANEGRM2CTSGPRTN3ALDH1A1 | |
| SCHEMBL20794186 | 0.61 | EHMT2 (0.42) | ELANEGRM2CTSGPRTN3ALDH1A1 | |
| SCHEMBL20780345 | 0.61 | EHMT2 (0.42) | ELANEGRM2CTSGPRTN3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | ELANE 1155/4885NPSR1 1096/4885GRM2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.